Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis

被引:7
|
作者
Yoshihara, Masato [1 ]
Tamauchi, Satoshi [1 ]
Iyoshi, Shohei [1 ,2 ]
Kitami, Kazuhisa [1 ]
Uno, Kaname [1 ,3 ]
Mogi, Kazumasa [1 ]
Kajiyama, Hiroaki [1 ]
机构
[1] Nagoya Univ, Dept Obstet & Gynecol, Grad Sch Med, Nagoya, Aichi, Japan
[2] Univ Freiburg, Inst Surg Pathol, Fac Med, Freiburg, Germany
[3] Lund Univ, Dept Lab Med, Fac Med, Lund, Sweden
关键词
Adjuvant Chemotherapy; Fertility Effect; Lymph Node Excision; Ovarian Cancer; Rupture; Spontaneous; FALLOPIAN-TUBE; SURVIVAL; CARCINOMA;
D O I
10.3802/jgo.2021.32.e66
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to examine the effects of incomplete surgery and adjuvant chemotherapy on the prognosis of patients with intraoperative rupture of capsulated stage I epithelial ovarian cancer (OvCa). Methods: A regional retrospective study was conducted between 1986 and 2019. Among 4,730 patients with malignant ovarian tumors, 534 women with International Federation of Gynecology and Obstetrics stage IA and IC1 epithelial OvCa were eligible. Differences in survival outcomes were examined between patients with stage IA and IC1 tumors and the effects of uterine preservation, complete-staging lymphadenectomy, and adjuvant chemotherapy were investigated by an in-depth subgroup analysis. To analyze therapeutic effects, baseline imbalances were adjusted using propensity score (PS). Results: The prognosis of patients with stage IC1 tumors was worse than those with stage IA. Surgical spill did not affect the site of recurrence. In the PS-adjusted subgroup analysis, uterine preservation (hazard ratio [HR]=1.669; 95% confidence interval [CI]=1.052-2.744), incomplete-staging lymphadenectomy (HR=1.689; 95% CI=1.211-2.355), and the omission of adjuvant chemotherapy (HR=3.729; 95% Cl=2.090-6.653) significantly increased the HR of recurrence for patients with stage IC1 tumors compared to those with stage IA tumors. Adjuvant chemotherapy decreased the impact of rupture with uterine preservation (HR=0.159; 95% CI=0.230-1.168) or incomplete-staging lymphadenectomy (HR=0.987; 95% CI=0.638-1.527). Conclusion: The present results suggest intraoperative rupture of capsulated stage I epithelial OvCa is associated with a poor prognosis. When chemotherapy is given for patients receiving incomplete surgery, there is no longer an increased risk of recurrence observed with the rupture.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The impact of chemotherapy and fertility-sparing surgery on recurrence of serous borderline ovarian tumors: A multi-institutional study of 491 patients
    Brooks, R.
    Ghezelayagh, T.
    Kiet, T.
    Fuh, K.
    Ueda, S.
    Longacre, T.
    Teng, N.
    Chen, L.
    Chan, J.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S5 - S5
  • [22] The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer Results From a Multi-Institutional Study
    Bogani, Giorgio
    Matteucci, Laura
    Tamberi, Stefano
    Arcangeli, Valentina
    Ditto, Antonino
    Maltese, Giuseppa
    Signorelli, Mauro
    Martinelli, Fabio
    Chiappa, Valentina
    Maggiore, Umberto Leone Roberti
    Perotto, Stefania
    Scaffa, Cono
    Comerci, Giuseppe
    Stefanetti, Marco
    Raspagliesi, Francesco
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (09) : 1856 - 1862
  • [23] Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study
    Kajiyama, Hiroaki
    Mizuno, Mika
    Shibata, Kiyosumi
    Yamamoto, Eiko
    Kawai, Michiyasu
    Nagasaka, Tetsuro
    Kikkawa, Fumitaka
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2014, 175 : 97 - 102
  • [24] Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer That Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?
    Bakkum-Gamez, Jamie N.
    Richardson, Debra L.
    Seamon, Leigh G.
    Aletti, Giovanni D.
    Powless, Cecelia A.
    Keeney, Gary L.
    O'Malley, David M.
    Cliby, William A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (07) : 1125 - 1131
  • [25] A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia
    Harutyunyan, Lilit
    Manvelyan, Evelina
    Karapetyan, Nune
    Bardakhchyan, Samvel
    Jilavyan, Aram
    Tamamyan, Gevorg
    Avagyan, Armen
    Safaryan, Liana
    Zohrabyan, Davit
    Movsisyan, Narine
    Avinyan, Anna
    Galoyan, Arevik
    Sargsyan, Mariam
    Harutyunyan, Martin
    Nersoyan, Hasmik
    Stepanyan, Arevik
    Galstyan, Armenuhi
    Danielyan, Samvel
    Muradyan, Armen
    Jilavyan, Gagik
    CURRENT ONCOLOGY, 2024, 31 (03) : 1323 - 1334
  • [26] Stage IVB epithelial ovarian cancer with isolated distant lymph node metastases: should a new substage be created? A multi-institutional analysis
    Long, Xingtao
    Zhou, Qi
    Zou, Dongling
    Li, Rengui
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A214 - A214
  • [27] A multi-institutional study of minimally invasive surgery compared to laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer
    Brown, Jubilee
    Barr, Alice
    Zhang, Yingao
    Davidson, Brittany
    Secord, Angeles Alvarez
    Drury, Lane
    Crane, Erin
    Tait, David
    Naumann, R. Wendel
    McNally, Leah
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S20 - S20
  • [28] Re: "Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase II trial." - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study.
    Ansaloni, Luca
    De Iaco, Pierandrea
    Frigerio, Luigi
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 279 - 281
  • [29] Complete Pathologic Response at Interval Debulking Surgery Following Neoadjuvant Chemotherapy Predicts Improved Survival in Women with Advanced Epithelial Ovarian Cancer in a Multi-institutional Cohort
    Liang, M.
    Prendergast, E.
    Staples, J.
    Holschneider, C.
    Cass, I.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 197 - 197
  • [30] Prognostic impact of pelvic and para-aortic lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis
    Yoshihara, Masato
    Kajiyama, Hiroaki
    Tamauchi, Satoshi
    Iyoshi, Shohei
    Yokoi, Akira
    Suzuki, Shiro
    Kawai, Michiyasu
    Nagasaka, Tetsuro
    Takahashi, Kunihiko
    Matsui, Shigeyuki
    Kikkawa, Fumitaka
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (02) : 145 - 151